Maintenance Therapy Duration and Considerations for Treatment Interruption

Video

Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.

Recent Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Tim Cortese
March 11th 2025
Article

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

Russ Conroy
February 25th 2025
Article

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.

Enfortumab Vedotin Combo Improves PFS/OS Vs Chemo in Urothelial Carcinoma

Kristi Rosa
February 15th 2025
Article

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.

The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

Dato-DXd Yields Encouraging Activity in Pretreated Advanced Bladder Cancer

Russ Conroy
February 15th 2025
Article

The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.